Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of “Buy” from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been given an average rating of “Buy” by the eleven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $16.5556.

IVA has been the subject of a number of research reports. Cantor Fitzgerald started coverage on Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently bought and sold shares of IVA. Creative Planning acquired a new position in shares of Inventiva in the 2nd quarter valued at $32,000. Virtu Financial LLC bought a new position in shares of Inventiva during the 4th quarter worth about $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva during the 4th quarter valued at about $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the 3rd quarter valued at about $116,000. Finally, Cerity Partners LLC bought a new stake in Inventiva in the fourth quarter valued at about $93,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Price Performance

IVA stock opened at $4.64 on Wednesday. Inventiva has a twelve month low of $3.35 and a twelve month high of $7.98. The business’s 50-day simple moving average is $4.22 and its 200 day simple moving average is $5.14.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.